Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-27
2011-10-25
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S465000, C540S474000, C435S007500, C424S001650, C424S001850
Reexamination Certificate
active
08044081
ABSTRACT:
Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.
REFERENCES:
patent: 5283342 (1994-02-01), Gustavson et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5578287 (1996-11-01), Theodore et al.
patent: 5608060 (1997-03-01), Axworthy et al.
patent: 5616690 (1997-04-01), Axworthy et al.
patent: 5624896 (1997-04-01), Axworthy et al.
patent: 5630996 (1997-05-01), Reno et al.
patent: 5847121 (1998-12-01), Yau et al.
patent: 5911969 (1999-06-01), Axworthy et al.
patent: 5914312 (1999-06-01), Axworthy et al.
patent: 5955605 (1999-09-01), Axworthy et al.
patent: 5968405 (1999-10-01), Yamasaki et al.
patent: 5976535 (1999-11-01), Fritzberg et al.
patent: 6075010 (2000-06-01), Theodore et al.
patent: 6217869 (2001-04-01), Meyer et al.
patent: 6287536 (2001-09-01), Reno et al.
patent: 6416738 (2002-07-01), Theodore et al.
patent: 2002/0015705 (2002-02-01), Theodore et al.
patent: 2002/0034511 (2002-03-01), Reno et al.
patent: 0 496 074 (1992-07-01), None
patent: 1 138 334 (2001-10-01), None
patent: WO 88 08422 (1988-11-01), None
patent: WO 93 25240 (1993-12-01), None
patent: WO 95 14493 (1995-06-01), None
patent: WO 97 10854 (1997-03-01), None
patent: WO 98/43678 (1998-10-01), None
Wilbur et al., “Biotin Reagents for Antibody Pretargeting. 4. Selection of Biotin Conjugates for in Vivo Application Based on Their Dissociation Rate from Avidin and Streptavidin,” Bioconjugate Chem. 2000, 11, pp. 569-583.
Renn et al., “New Approaches to Delivering Metal-Labeled Antibodies to Tumors: Synthesis and Characterization of new Biotinyl Chelate Conjugates for Pre-Targeted Diagnosis and Therapy,” Journal of Controlled Release, 39 (1996), pp. 239-249.
Wilbur et al., “Trifunctional Biotinylation Reagents Which Contain a Radiometal Binding Chelate and an Isothiocyanate Group for Conjugation with Biomolecules,” J. Labelled Cpd. Radiopharm, 44, Suppl. 1 (2001), pp. S741-S743.
Paganelli et al, “Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin”, European Journal of Nuclear Medicine, vol. 26, No. 4, Apr. 1999, pp. 348-357; XP008019281.
Paganelli, G. et al., “IART®: Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation” The Breast (2007) 16, p. 17-26.
Paganelli, G. et al., “Intraoperative avidination for radionuclide treatment: a prospective new development to accelerate radiotherapy in breast cancer” Clin. Cancer Res. 2007:13(18Suppl) p. 5646s-5651s.
Chinol Marco
Ginanneschi Mauro
Paganelli Giovanni
Coleman Brenda
Lucas & Mercanti LLP
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Aminoderivative of biotin and their conjugates with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoderivative of biotin and their conjugates with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoderivative of biotin and their conjugates with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261935